Friday, May 26, 2023
News on Pathogens and Preparedness
Global Biodefense
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe
No Result
View All Result
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe
No Result
View All Result
Global Biodefense
No Result
View All Result
Home Industry News

Emergent BioSolutions Secures Rights to Pandemic Influenza Vaccine Candidate

by Global Biodefense Staff
January 8, 2013

Pandemic InfluenzaEmergent BioSolutions Inc., maker of the only U.S. approved anthrax vaccine, announced at the end of 2012 it has signed a license agreement with VaxInnate Corporation under which Emergent acquired the exclusive right to manufacture and sell VaxInnate’s pandemic influenza vaccine candidate.

Last year the Biomedical Advanced Research and Development Authority (BARDA) established Emergent as one of several Centers for Innovation in Advanced Development and Manufacturing under an initial 8-year, $163 million contract . BARDA requirements to secure a pandemic influenza cadidate were fulfilled by the deal between VaxInnate and Emergent.

“This transaction, which secures manufacturing rights to a next-generation pandemic influenza vaccine candidate, is a step towards satisfying Emergent’s commitment to BARDA as a Center for Innovation in Advanced Development and Manufacturing,” Daniel J. Abdun-Nabi, president and CEO of Emergent, said in a statement. “Our public-private partnership with BARDA, which taps into our core manufacturing capabilities and infrastructure, provides a real opportunity to make significant progress to address the nation’s medical countermeasure manufacturing requirements.”

VaxInnate utilizes Toll-Like Receptors (TLR) technology to produce vaccines as soluble biopharmaceutical grade proteins in bacteria.  The approach relies on the immune system to recognize certain molecular patterns associated with invading pathogens, triggering an adaptive immune response including the production of antibodies. The company’s vaccines combine proteins of vaccine antigen (such as the influenza HA) and bacterial flagellin, a component of the long hair-like tails that help bacteria swim and one of the molecular patterns recognized by TLRs.

Physically linking flagellin to antigens leads to a more potent vaccine than just administering a mixture of the two unattached components. The method has been demonstrated to produce robust protective immune responses in animal models to several pathogens including Dengue Virus, Japanese Encephalitis Virus and West Nile Virus, in addition to influenza. Because flagellin is a stable bacterial protein, these fusion products are simple to make using recombinant DNA techniques. The ability to rapidly develop and manufacture large quantities of the fusion product vaccines makes them ideally suited for responding to seasonal variants of influenza, or emerging pandemic viruses.

VaxInnate will continue to develop the candidate under its current contract with the Biomedical Advanced Research and Development Authority, while Emergent will produce it, using flexible manufacturing technology. 

Tags: Animal ModelsASPRBARDAHHSInfluenzaPandemicVaccinesWest Nile

Related Posts

Vials of finished vaccines
Funding News

UK Biomanufacturing Fund to Bolster Supply Chain Resilience and Pandemic Preparedness

May 26, 2023
Aptitude Awarded Up to $54M BARDA Funding for At-Home Diagnostics
Industry News

Aptitude Awarded Up to $54M BARDA Funding for At-Home Diagnostics

April 20, 2023
Medical Countermeasures

Scientists Design Molecule to Slow SARS-Cov-2 Infection

March 29, 2023
DARPA Selects Teams to Develop Vaccine Durability Prediction Model
Medical Countermeasures

DARPA Selects Teams to Develop Vaccine Durability Prediction Model

January 13, 2023
Load More

Latest News

Vials of finished vaccines

UK Biomanufacturing Fund to Bolster Supply Chain Resilience and Pandemic Preparedness

May 26, 2023
Dr. Sen Pei Discusses Challenges in Forecasting Antimicrobial Resistance

Dr. Sen Pei Discusses Challenges in Forecasting Antimicrobial Resistance

April 26, 2023
Biodefense Headlines – 25 April 2023

Biodefense Headlines – 25 April 2023

April 25, 2023
Aptitude Awarded Up to $54M BARDA Funding for At-Home Diagnostics

Aptitude Awarded Up to $54M BARDA Funding for At-Home Diagnostics

April 20, 2023

Subscribe

  • About
  • Contact
  • Privacy
  • Subscribe

© 2023 Stemar Media Group LLC

No Result
View All Result
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe

© 2023 Stemar Media Group LLC